For the most up to date information on COVID-19 please visit the Department of Health website. Learn more about how the AIHW is assisting the COVID-19 response and how our other work is affected. Our Covid-19 related resources page includes a list of some existing resources which may be useful when researching issues related to COVID-19.
Australian Institute of Health and Welfare 2012. Cervical screening in Australia 2009-2010. Cat. no. CAN 63. Canberra: AIHW.
Australian Institute of Health and Welfare. (2012). Cervical screening in Australia 2009-2010. Canberra: AIHW.
Australian Institute of Health and Welfare. Cervical screening in Australia 2009-2010. AIHW, 2012.
Australian Institute of Health and Welfare. Cervical screening in Australia 2009-2010. Canberra: AIHW; 2012.
Australian Institute of Health and Welfare 2012, Cervical screening in Australia 2009-2010, AIHW, Canberra.
Get citations as an Endnote file:
PDF | 1.5Mb
Cervical screening in Australia 2009-2010 presents the latest national statistics monitoring the National Cervical Screening Program, which aims to reduce incidence, morbidity and mortality from cervical cancer.
There were 637 new cases of cervical cancer diagnosed in 2008, and 131 women died from cervical cancer in 2007
Incidence and mortality have both halved since the NCSP was introduced in 1991
Only 14% of women with a negative Pap test in 2009 rescreened earlier than recommended
In 2009–2010, more than 3.6 million women participated in the NCSP. This was 57% of women in the target population
The National Cervical Screening Program (NCSP) aims to reduce cervical cancer cases, as well as illness and death resulting from cervical cancer in Australia, through an organised approach to cervical screening aimed at detecting and treating high-grade abnormalities before possible progression to cervical cancer. The target group is women aged 20–69.
This report is the latest in the Cervical screening in Australia series, which is published annually to provide regular monitoring of national participation and performance for the NCSP. While the previous report covered the 2008–2009 period of participation, this report provides data for the 2009–2010 period of participation in the NCSP, as well as the latest available cervical cancer incidence and mortality data (from sources outside the NCSP).
The following statistics refer to the latest data available for women aged 20–69.
There were 637 new cases of cervical cancer diagnosed in 2008, and 131 women died from this in 2007. This is equivalent to 9 new cases and 2 deaths per 100,000 women, respectively.
Incidence and mortality have both halved since the NCSP was introduced in 1991, remaining at their historic lows of 9 new cases and 2 deaths per 100,000 women since 2002.
The incidence of cervical cancer in Aboriginal and Torres Strait Islander women was more than twice that of non-Indigenous women, and mortality of Aboriginal and Torres Strait Islander women was 5 times the non-Indigenous rate.
In 2009–2010, more than 3.6 million women participated in the NCSP. This was 57% of women in the population (after adjustment to exclude those without a cervix).
Participation was similar across remoteness areas, with only 3 percentage points separating the highest participation of 58% in Major cities from the lowest of 55% in Remote areas.
Participation showed greater differences across socioeconomic status of residence, and a clear trend of increasing participation with increasing socioeconomic status from 52% of women residing in areas of lowest socioeconomic status to 63% of women residing in areas of highest socioeconomic status.
Participation by Aboriginal and Torres Strait Islander women is not available, although there is evidence that this population group is under-screened.
Only 14% of women with a negative Pap test in 2009 rescreened earlier than recommended.
Of the women sent a 27-month reminder letter by a cervical cytology register in 2009, 32% rescreened within 3 months, indicating that this letter acts as a prompt for many women.
In 2010, for every 1,000 women screened, 9 women had a high-grade abnormality detected by histology, providing an opportunity for treatment before possible progression to cancer.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.